Tübingen's messenger RNA vaccine and drug developer's latest round includes a $171m investment by strategic partner GlaxoSmithKline.

CureVac, a Germany-based RNA therapy spinout of Eberhard Karls University of Tübingen, closed a $640m financing round on Tuesday that included $171m from pharmaceutical firm GlaxoSmithKline, which signed a strategic partnership with it this week. The round includes $343m in the form of the funding commitment made by German development bank KfW last month and…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.